Participant receives both curcumin and prednisolone. Curcumin for 11 days, prednisolone for 10 days. Curcumin: 2 tablets (each contains 100 mg curcumin) twice daily. Prednisolon: 50 mg (capsule) every morning

Participant receives prednisolone and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon: 50 mg (capsule) every morning

Participant receives prednisolone.placebo and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone-placebo for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon-placebo: One capsule every morning.

Insulin Resistance

Non-Alcoholic Fatty Liver Disease

Curcumin is given together with prednisolone

Curcumin Liposome

Prednisolone is given together with curcumin-placebo

Prednisolone

Prednisolone-placebo is given together with curcumin-placebo

Placebos

Center for Clinical Metabolic Research

The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance

The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance in Overweight and Obese Participants

homeostatic model assessment of insulin resistance is calculated before and after intervention

Measured by MR spectroscopy of the liver (unit: %)

Estimated by collecting urin for 4-5 hours, measuring volume of urine and urea concentration

Feces sample before and after intervention

subcutaneously, interstitial measurement (concentration of glucose) every 15 minutes in the intervention period

icare 100 tonometer measurement (unit: mmHg)

measured by bioimpedance (units: kg and %)

MR-spectroscopy measurement (unit: cm3 at L3-level, 1 cm thick slice)

visual analogue scale evaluation (no visible numbers/points, just a clear line)

Evaluated by calculating ingested meal at ad libitum meal at test days (unit: grams and calories)

Visual analogue scale (no points/number visible, just a clear line)

Pernille Høgh Hellmann

Medical Doctor, primary investigator

University Hospital, Gentofte, Copenhagen

After study day 1, participants are randomized (1:1:1) to one of three treatments: 1) Prednisolon and Curcumin, 2) Prednisolon and placebo or 3) Placebo and placebo.

Subjects in group A get citicoline 1000 mg per day for 60 days

Subjects in group B get placebo for 60 days.

Non-arteritic Anterior Ischemic Optic Neuropathy

Citicoline 1000 mg will be repackaged and given to Group A for 60 days

Group A Citicoline 1000 mg oral tablet

Placebo will be repackaged and given to Group B for 60 days

Group B placebo oral tablet

Departemen Mata Fakultas Kedokteran Universitas Indonesia- RSCM Kirana

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study

amplitude measured from the valley of N35 to the peak of P50 with pattern electroretinography

amplitude measured from peak of P50 to valley of N95 with pattern electroretinography

anatomical cross-sectional examination of retinal ganglion cells using optical coherence tomography (OCT) CirrusTM HD-OCT 5000. The mode is panomap ganglion cell analysis: Macular Cube 512x128 and 200x200 cube Optic disc. Examination is repeated with minimal attention to signal strength is ≥ 5.

visual field test results using Humphrey HFA II-i 750, 24-2 threshold. Examination is repeated by taking into account the confidence index that meets the three criteria below:
Fixation losses ≤ 20%
False positive ≤ 15%
False negative ≤ 20-30%
The parameters assessed are:
The mean deviation (MD): the result of the average sensitivity of the retina of patients compared with the normal population. This figure is obtained from the total deviation.
Pattern standard deviation (PSD): the result of the average sensitivity of the retina of patients who have adapted and showed a localized area index. This figure is obtained from the pattern deviation.

Valen Chia

dr. Valenchia

Sample of 20 people for each treatment group (Group A: citicoline and group B : placebo). Both group were given drug (whether citicoline or placebo) for 60 days.

The allocation of the subject is done by using block randomization. Randomization will be performed by a third party before the study began. Number randomization results will be incorporated into the white envelope sealed and classified into group A (got citcoline) or group B (placebo) in accordance with the results of randomization. Neither the participant, investigator nor the outcome assessor know whether the patient is classified into group A or B.

children aged 6 months - 18 years, diagnosed with an initial episode of INS occurring from the first of July 2011 to the 31st of june 2013.

Nephrotic Syndrome

Azienda Ospedaliera-Universitaria Sant'Orsola Malpighi

PO Salesi, SOS Centro di Riferimento Regionale di Nefrologia e Dialisi Pediatrica

Ospedale Pediatrico Giovanni XXIII

Azienda Ospedaliera Universitaria Meyer, SOD Complessa Nefrologia Pediatrica

Istituto Giannina Gaslini, Dept of Pediatric Nephrology

AOU Policlinico G Martino UOS dipartimentale Nefrologia e Reumatologia pediatrica

Fondazione IRCCS Ca' Granda Ospedale MAggiore Policlinico, UOC Nefrologia e Dialisi

Ospedale dei bambini Di Cristina, UOC Nefrologia Pediatrica

Ospedale degli Angeli, Dept of Pediatrics

Ospedale Pediatrico Burlo Garofalo

Università di Trieste, Department of Life Sciences

Steroid Treatment of Idiopathic Nephrotic Syndrome

Steroid Treatment of Childhood Idiopathic Nephrotic Syndrome: Epidemiology, Therapeutic Adequacy, Medium and Long Term Outcomes. A Prospective Observational Cohort Study.

Giovanni Montini

Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi

IL Sogno di Stefano

Nando and Elsa Peretti Foundation

Obstructive Sleep Apnea Syndrome

measurement of ocular blood flow with a laser Doppler flowmeter

glaucoma/triglyceride

The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Steroid Treatment of Idiopathic Nephrotic Syndrome

Study of Ocular Blood Flow in Patients With Glaucoma and/or Obstructive Sleep Apnea Syndrome (OSAS)

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı